TARSUS PHARMACEUTICALS, INC. Amortization of Intangible Assets
TARSUS PHARMACEUTICALS, INC. (TARS) reported Amortization of Intangible Assets of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $200.00K, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $240.00K, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $241.00K, a 0.42% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $200.00K, a 100.00% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $961.00K, a 77.96% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $540.00K, a 306.02% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $133.00K.
- TARSUS PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $0.00.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-06 | $480.00K 10-Q · filed 2026-08-06 | $681.00K derived: sum of 3 quarters · filed 2026-08-06 | $881.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $240.00K 10-Q · filed 2026-05-06 | $481.00K derived: sum of 2 quarters · filed 2026-05-06 | $681.00K derived: sum of 3 quarters · filed 2026-05-06 | $881.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $441.00K derived: sum of 2 quarters · filed 2026-02-23 | $641.00K derived: sum of 3 quarters · filed 2026-08-06 | $961.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-04 | $400.00K derived: sum of 2 quarters · filed 2026-08-06 | $720.00K 10-Q · filed 2025-11-04 | $880.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-06 | $480.00K 10-Q · filed 2026-08-06 | $680.00K derived: sum of 3 quarters · filed 2026-08-06 | $780.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $240.00K 10-Q · filed 2026-05-06 | $480.00K derived: sum of 2 quarters · filed 2026-05-06 | $580.00K derived: sum of 3 quarters · filed 2026-05-06 | $680.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $340.00K derived: sum of 2 quarters · filed 2026-02-23 | $440.00K derived: sum of 3 quarters · filed 2026-02-23 | $540.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-04 | $200.00K derived: sum of 2 quarters · filed 2025-11-04 | $300.00K 10-Q · filed 2025-11-04 | $400.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-06 | $200.00K 10-Q · filed 2025-08-06 | $300.00K derived: sum of 3 quarters · filed 2026-02-23 | $300.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-01 | $200.00K derived: sum of 2 quarters · filed 2026-02-23 | $200.00K derived: sum of 3 quarters · filed 2026-02-23 | $200.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $100.00K derived: sum of 2 quarters · filed 2026-02-23 | $100.00K derived: sum of 3 quarters · filed 2026-02-23 | $133.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $33.00K 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |